Avadel Pharmaceuticals to Announce Q2 2024 Results and Corporate Update on August 8

DUBLIN, Aug. 01, 2024 - Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company dedicated to improving lives through innovative medical solutions, announced today it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 8, 2024. This event aims to provide a corporate update and discuss the Company’s financial results for the second quarter ending June 30, 2024.

Interested parties can access a live audio webcast of the call by visiting the investor relations section on Avadel’s official website, www.avadel.com. For those unable to participate live, a replay of the webcast will be available on the website for 90 days following the event. Participants are encouraged to register for the conference call at least 10 minutes before the scheduled start.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company committed to transforming medicines to improve lives. The company focuses on creating innovative medication solutions to address the challenges patients face with existing treatment options. Avadel’s flagship commercial product, LUMRYZ™, has received approval from the U.S. Food & Drug Administration (FDA). It stands out as the first and only once-at-bedtime oxybate designed to treat cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!